Most importantly, FGL1 will be a potential biomarker for predicting the outcome of PD-1/PD-L1 blockade therapy, since high plasma FGL1 levels were reported to be significantly correlated with a worse therapeutic response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma patients [50, 166]. This evidence concerns the gene CD274 and melanoma.